Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Ovarian Neoplasms 5Triple Negative Breast Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Recurrence 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Kenny-Caffey syndrome, Type 1 1Esophageal Squamous Cell Carcinoma 1Breast Neoplasms 1Advanced Solid Tumors 1

Interventions

Gemcitabine 78Fluorouracil 27Oxaliplatin 24130-nm albumin-bound paclitaxel 24Leucovorin 18Capecitabine 15Albumin-Bound Paclitaxel 15S 1 (combination) 14Taxes 12Irinotecan 11pembrolizumab 9folfirinox 9Radiosurgery 9Radiotherapy 7Drug Therapy 7Cisplatin 7irinotecan sucrosofate 6Pancreaticoduodenectomy 5Paclitaxel 5Injections 5Docetaxel 5Blood Specimen Collection 5apatinib 4Radiofrequency Ablation 4Radiation 4Biopsy 4tislelizumab 3rubitecan 3nimotuzumab 3camrelizumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Pancreatic Neoplasms × fluzoparib × Clear all
NCT04425876 2020-12-31

A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Resectable Pancreatic Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Unknown
74 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡